{"id":1915,"date":"2015-09-07T07:06:03","date_gmt":"2015-09-07T11:06:03","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=1915"},"modified":"2015-10-07T03:32:14","modified_gmt":"2015-10-07T07:32:14","slug":"dalbavancin-approval-issues-a-case-of-much-ado-about-nothing","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2015\/09\/07\/1915\/dalbavancin-approval-issues-a-case-of-much-ado-about-nothing\/","title":{"rendered":"Dalbavancin Approval Issues: A Case of Much Ado About Nothing"},"content":{"rendered":"

\"Dalbavancin<\/a><\/p>\n

Dalbavancin has changed hands a few times in its development history, moving\u00a0from Lilly to Vicuron, then Pfizer and ultimately Durata. The original NDA for dalbavancin was submitted to FDA on Dec. 21, 2004.\u00a0 Pfizer acquired dalbavancin\u00a0as a \u201cPhase 3 completed\u201d drug ready for world-wide marketing on June 15, 2005. The drug was eventually approved on May 23, 2014.\u00a0 What a delay! \u00a0What an odyssey!<\/p>\n

The main issues FDA brought up when it issued an \u2018Approvable Letter’ on Dec 20, 2007 were related to (1) GMP issues, and (2) the lack of justification of the NI margin of 10% in pivotal trial VER001-8.<\/p>\n

We are not told the\u00a0details of the GMP \/ CMC issues but it is not something that\u00a0would take 7 years to fix. It was the second issue, i.e., the NI margin justification, which held up the submission, made Pfizer throw in the towel, and forced Durata to conduct 2 new Phase 3 trials resulting in a much delayed\u00a0approval.<\/p>\n

FDA\u2019s mandate is and remains to safeguard the public from the dangers of a thalidomide, ethylene glycol and medical quackery. Nowadays, new compounds that were poorly studied, poorly documented, without proper safety assessments, that lack GMP or GCP standards are appropriately being stopped\u00a0by the FDA watchdogs. There is\u00a0still\u00a0the occasional case of egregious misconduct, by industry not living up to its sponsor responsibilities, and by investigators putting financial benefits ahead of patient concerns. This is a problem across the board and affects other therapeutic areas as well; we hear about them periodically from whistle blowers inside and outside the Agency.<\/p>\n

However, even in a high-quality submission \u2013 one without major issues related to the Big 3: Efficacy, Safety, Quality \u2013 there is an inherent residual risk (call it beta) which is intrinsic to the development of any NCE; it is not reducible to Zero. Hence, regulators need to use judgement, or wisdom, based on precedent, based on in-house experience, based on the ancillary contextual information sometimes only available to FDA.<\/p>\n

Every FDA reviewer\u2019s nightmare is having given the green light to a drug like [insert your favorite example<\/span><\/em>] that became a disaster. However, there really weren’t any in recent memory.\u00a0 Would telithromycin (Ketek) have been a disaster if it had been unleashed on the US? \u00a0Unlikely. Already approved temafloxacin (Omniflox) was probably the most dangerous drug (it caused HUS) but surveillance measures were in place at the time and it was withdrawn from the market once this most unusual adverse event became known. Daptomycin (Cubicin), often cited for its failed pneumonia study, was found out about in the course of clinical investigation, not stopped by an astute FDA regulatory reviewer \u00e0 la Dr. Kelly.<\/p>\n

The last disasters we are aware of were those of FIAU (hepatic \/ mitochondrial toxicity) and TeGenero’s TGN-1412 (cytokine storm). In the former, early cases of mortality were overlooked that \u2013 with 20\/20 hindsight – were (maybe) preventable. In the latter, there were\u00a0no early warnings signs.<\/p>\n

So, how much of a ‘risk’ represents a “non-justified NI margin of 10%”, a margin used by many other developers in the past?<\/p>\n

When regulators want to \u2018diversify risk\u2019, they have several mechanisms to do so:\u00a0 By calling an AIDAC (benign approach) or by delaying approval demanding new trials (the nuclear option). \u00a0Requesting a new set of clinical trials is tantamount to killing the drug: it usually\u00a0makes industry lose interest in the project and give up on it.<\/p>\n

In the case of Dalvance, the good folks at Durata chose to bite the bullet and redo the Phase 3 program. They did so with some safeguards, by obtaining an SPA, following the new thinking at FDA re: ABSSSI to a\u00a0T, becoming Snodgrass [1,2] experts, and learning to love the FDA\u2019s ABSSSI Guidance with its contrived NI justifications for M1, M2 and delta discounts.<\/p>\n

Seven (7) years later we now have a new set of FDA-compliant Dalvance Phase 3 data. They show that not only at the EOT, the TOC visit and the 30-day f\/u visit are clinical and bacteriologic responses between dalbavancin and comparator similar ,but also at the incredibly important<\/em> Day 2-3 timepoint when lesion sizes are compared.<\/p>\n

Obtaining this additional\u00a0piece of information, of questionable clinical relevance at best and not endorsed by EMA, came at an incredible cost for industry. It also denied patients and caregivers access to a drug which had some really unique features. Unless there is more to the early rejection which did not make it into the public domain, the regulatory delay tactics in the case of dalbavancin are totally unjustified and\u00a0incomprehensible.<\/p>\n

Please take the time and vote below – your opinion matters. \u00a0Thank you!
\n<\/strong><\/span>[poll id=”5″]<\/p>\n

\n

P.S. #1:\u00a0 On March 31, 2014 the FDA AIDAC voted 12:0 in favor of dalbavancin approval
\nP.S. #2:\u00a0 There was no FDA AIDAC at the time of the 2007 dossier\u00a0review prior to issue of the Approvable Letter
\nP.S. #3: \u00a0The\u00a0Medical Review of the Dalvance dossier lists a total of 35 compounds currently approved for cSSSI \/ ABSSSI, most based on NI studies with a unjustified delta of 10%.<\/p>\n

References:<\/strong>
\nFor a review of studies comprising the original Dalbavancin submission see:
\nJ. Bennett:\u00a0Dalbavancin in the treatment of complicated skin\u00a0and soft-tissue infections: a review.\u00a0Therapeutics and Clinical Risk Management 2008;4: 31
\n[1]\u00a0\u00a0Snodgrass W. 1937 \u00a0\u00a0BMJ, 2:101
\n[2] \u00a0Snodgrass W. \u00a01937; BMJ, 2:1167<\/p>\n

Abbreviations:
\n<\/strong>NI \u00a0 \u00a0 \u00a0 \u00a0 \u00a0non-inferiority
\nSPA \u00a0 \u00a0 \u00a0special protocol assessment
\nAIDAC \u00a0Anti-Infectives Drug Advisory Committee
\nHUS \u00a0 \u00a0 \u00a0hemolytic-uremic syndrome
\nEOT \u00a0 \u00a0 \u00a0End-of-Therapy
\nTOC \u00a0 \u00a0 \u00a0Test-of-Cure<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Dalbavancin has changed hands a few times in its development history, moving\u00a0from Lilly to Vicuron, then Pfizer and ultimately Durata. The original NDA for dalbavancin was submitted to FDA on Dec. 21, 2004.\u00a0 Pfizer acquired dalbavancin\u00a0as a \u201cPhase 3 completed\u201d drug ready for world-wide marketing on June 15, 2005. The Continue reading Dalbavancin Approval Issues: A Case of Much Ado About Nothing<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[19,18],"tags":[778,1315,403,1316,229,66,85,228,1319,625,1320,5,1317,785,93,153,1006,655,1371,154,715,1318,1017,786,1005,1018,1022,659],"class_list":["post-1915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qidp_antibiotic","category-the_viewpoint","tag-aidac","tag-anti-infective-drug-advisory-committee","tag-antibiotic-blog","tag-approvable-letter","tag-cubicin","tag-dalbavancin","tag-dalvance","tag-daptomycin","tag-dr-kelly","tag-ema","tag-ethylene-glycol","tag-fda","tag-fiau","tag-ketek","tag-lilly","tag-non-inferiority","tag-omniflox","tag-pfizer","tag-qidp","tag-snodgrass","tag-spa","tag-special-protocol-assesssment","tag-tegenero","tag-telithromycin","tag-temafloxacin","tag-tgn-1412","tag-thalidomide","tag-vicuron"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Dalbavancin-slider-copy.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-uT","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1105,"url":"https:\/\/allphasepharma.com\/dir\/2014\/11\/02\/1105\/dalbavancin-sale-to-actavis\/","url_meta":{"origin":1915,"position":0},"title":"Dalbavancin Sale to Actavis","author":"Harald","date":"November 2, 2014","format":false,"excerpt":"When Pfizer bought dalbavancin and anidulofungin from Vicuron in 2005, it shelled out USD 1.9 billion for both Phase 3 drugs.\u00a0 One can argue whether each drugs had the same commercial value for Pfizer but it is safe to assume that dalbavancin was valued at approx. USD 1 billion at\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/DalvanceActavis.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/DalvanceActavis.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/11\/DalvanceActavis.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":157,"url":"https:\/\/allphasepharma.com\/dir\/2014\/04\/22\/157\/antibiotics-with-qidp-designation\/","url_meta":{"origin":1915,"position":1},"title":"Antibiotics with QIDP Designation – – – Updated 9-30-14","author":"Harald","date":"April 22, 2014","format":false,"excerpt":"For the latest QIDP listing, please click HERE \u00a0 Since\u00a0FDA issued the QIDP designation in 2012, many companies have requested this important 'label'. \u00a0Which should not come as a surprise: QIDP status confers significant benefits - and there is no downside. While an official FDA list of drugs that have\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":249,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/05\/249\/here-they-are-dalbavancin-oritavancin-the-new-long-acting-lipoglycopeptides\/","url_meta":{"origin":1915,"position":2},"title":"Here They Are: Dalbavancin and Oritavancin \u2013 The New Long-Acting Lipoglycopeptides","author":"Harald","date":"June 5, 2014","format":false,"excerpt":"The development history of glycopeptide drugs is anything but normal.\u00a0 Daptomycin (Cubicin\u00ae) was abandoned by Lilly but resurrected by Francis Tally at Cubist by adjusting the dosing schedule to once daily and careful uptitration.\u00a0 The drug did superbly in a landmark endocarditis trial and everything looked rosy.\u00a0 Then we learned\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":439,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/02\/439\/adequate-penetration-of-daptomycin-into-bone-tissue\/","url_meta":{"origin":1915,"position":3},"title":"Adequate Penetration of Daptomycin Into Bone Tissue","author":"Harald","date":"July 2, 2014","format":false,"excerpt":"After a single high dose of (8 or 10 mg\/kg BW) of daptomycin IV, bone levels were measured in plasma and trabecular bone obtained during hip or knee surgery of 16 patients.[1] At the time of surgery, mean concentrations in plasma and synovial fluid were 39 and 22 \u00b5g\/mL, respectively.\u00a0\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"daptomycin","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/daptomycin-300x175.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1408,"url":"https:\/\/allphasepharma.com\/dir\/2015\/05\/07\/1408\/no-such-thing-as-a-free-ride\/","url_meta":{"origin":1915,"position":4},"title":"No Such Thing as a Free Ride\u2026","author":"Harald","date":"May 7, 2015","format":false,"excerpt":"..when it comes to FDA review of antibiotic NDAs.\u00a0 Some seem to have forgotten the dismal record of antibiotic approvals in the last 15 years, and the long list of failed submissions.\u00a0 Many failed not because of lack of efficacy or a bad safety profile but because of changes in\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"theBMJ","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/05\/theBMJ.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1946,"url":"https:\/\/allphasepharma.com\/dir\/2015\/09\/21\/1946\/allphase-pharma-the-first-100-blog-posts\/","url_meta":{"origin":1915,"position":5},"title":"ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS","author":"Harald","date":"September 21, 2015","format":false,"excerpt":"After the first 100 blogs, it is appropriate to reflect on reader preferences.\u00a0 When I arbitrarily select a topic, it is not always clear whether what interests me also interests you. Since its start\u00a01\u00bd years ago, this blog has grown steadily in readership. \u00a0So we did a few things right\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"blog100 - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/blog100-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/blog100-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/blog100-slider.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=1915"}],"version-history":[{"count":19,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1915\/revisions"}],"predecessor-version":[{"id":2010,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1915\/revisions\/2010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/1917"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=1915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=1915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=1915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}